97 / 154
A B S T R A C T S
S67
Table 2 (abstract P053) – Multinomial Regression comparing
prevalence of smoking between cancer survivors and the healthy
public. (Adjusting for Age, gender, education and marital status)
Odds Ratio (CI)
P
Former Smoker (Vs Never Smoker)
Cancer
1
(0.029)
No Cancer
0.801 (.656-.977)
Current Smoker (Vs Never Smoker)
Cancer
1
(0.215)
No Cancer
0.849 (.656-1.099)
Former Smoker (Vs Current Smoker)
Cancer
1
(0.657)
No Cancer
0.943 (.729-1.221)
CI= 95% confidence interval
References
:
[1] Cancer research UK. Cancer statistics key stats, all cancers
combined. London. Cancer research Uk. 2015
[2] Yabroff KR, LawrenceWF, Clauser S, et al. Burden of illness in
cancer survivors: findings from a population-based national
sample. J Natl Cancer Inst. 2004 Sep 1;96(17):1322-30
[3] Demark-WahnefriedW, Aziz NM, Rowland JH and Pinto BM.
Riding the crest of the teachable moment: promoting long-
term health after the diagnosis of cancer. J Clin Oncol. 2005
Aug 20;23(24):5814-30.
Disclosure of interest:
None declared
Keywords:
Cancer survivor, depression, health behaviours,
quality of Life
P054
ASSESSMENT OF RENAL FUNCTION AMONG PATIENTS
WITH BONE METASTASES FROM SOLID TUMORS
G. S. Bhattacharyya
1,
*, H. Malhotra
2
, K. Govindbabu
3
, R. Singh
4
,
A. Vora
5
, T. P. Sahoo
6
1
Medical Oncology, Fortis Hospital, Anandapur, EM Bye Pass Road,
Kolkata, (WB), India, Kolkata,
2
Medical Oncology, SMS Medical
College & Hospital, Jaipur,
3
Medical Oncology, Kidwai Memorial
Institute of Oncology, Bangalore,
4
Medical Oncology, HCG-SMH
Cancer Centre,
5
Medical Oncology, MaxHospital, New Delhi,
6
Medical Oncology, Jawaharlal Nehru Cancer Hospital & Research
Centre, Bhopal, India
Introduction:
Renal dysfunction is common in geratric
patients; it is more common in elderly patients. It is common
Objectives:
To examine the change in renal function among
patients with bone metastases (BM) from solid tumors (ST).
Methods:
A retrospective cohort study was conducted
database, containing medical records oncology/hematology
practice in India. The study sample included adults (age
65
years) diagnosed with a single ST and BM between 01/01/2012
through 09/30/2013. Changes in renal function from baseline
(6 months prior to the BM diagnosis) over the follow-up period
were assessed. The outcomes of interest include clinically-
meaningful increase in serum creatinine (SeCr) [defined as
0.5 mg/dL increase in patients with normal baseline levels
(<1.4 mg/dL), and 1.0 mg/dL increase in those with elevated
baseline levels (
1.4 mg/dL)], estimated glomerular filtration
rate (eGFR), and chronic kidney disease (CKD) stage (1:
eGFR
90 to 5: eGFR<15). Descriptive analysis was conducted
to examine baseline patient characteristics and change in
renal function.
Results:
A total of 380 patients met the eligibility criteria;
majority of them were female (52%), India (80%), with mean
age of 70 years (Standard Deviation [SD]: 12), mean SeCr of 1.0
(SD: 0.5), and mean eGFR of 77 (SD: 23) at baseline. During a
median follow-up of 191 days after BM diagnosis, an average
11-point (SD: 17) reduction (relative reduction: 13%) in eGFR
from baseline was observed. Clinically-meaningful increases
in SeCr were observed in 10.8% of the patients overall; among
7.2% patients from elevated (n=706) and 11.3% from normal
(n=5,674) baseline SeCr levels. Increases in CKD stage from
baseline levels were observed in 36% of the patients.
Conclusion:
Worsened renal function was observed among
patients with ST and BM. Given the use of bone targeting
agents in this patient population, future analysis is needed
to understand the impact of those agents, such as zoledronic
acid, on renal function.
Disclosure of interest:
None declared
Keywords:
Renal failure, bone mets, solid tumor
P055
PROPHYLACTIC USE OF FILGRASTIM TO MANAGE
CHEMOTHERAPY-INDUCED NEUTROPENIA IN ELDERLY
PATIENTS
I. Krakrowski
1
, J.-L. Mouysset
2
, D. Burlacu
3
, K. Benabed
4
,
M. Hacini
5
, A. El Weshi
6
, P. Janoray
7
, R. Diab
8,
*, D. Badinand
9
,
M. Gardner
10
, N. Sakek
11
, E. Fabre
12
, N. Jovenin
13
, S. Corbinais
14
,
K. Laribi
15
1
Institut Bergonié, Bordeaux,
2
Clinique Rambot Provençale, Aix en
Provence,
3
Centre Hospitalier Henri Mondor, Aurillac,
4
Hopital Côte
de Nacre, Caen,
5
CH de Chambery, Chambery,
6
CH du Cotentin site
de Cherbourg, Cherbourg Octeville,
7
Institut de Cancérologie de
Bourgogne, Dijon,
8
CHI Emile Durkheim Site Epinal, Epinal,
9
CHU
La Timone, Marseille,
10
Hôpital Clinique Claude Bernard-Centre
Privé de Radiothérapie, Metz,
11
Hôpital Nord Franche Comté Site Le
Mittan, Montbeliard,
12
Hôpital Européen Georges Pompidou (HEGP),
Assistance Publique Hôpitaux de Paris (AP-HP), Paris,
13
Clinique
François 1er, Saint Dizier,
14
CH St Malo, St Malo,
15
CH Le Mans, Le
Mans, France
Introduction:
Neutropenia, one of the most frequent dose-
limiting toxicities in cancer patients, can generate serious
life-threatening complications, especially in elderly patients.
Neutropenic complications are not only more frequent
among older patients but also more severe. In order to prevent
these complications, elderly patients are often treated by less
invasive chemotherapy protocols whereas the use of low dose
or shorter duration chemotherapy decreases overall survival.
Few studies are currently available among this specific
subpopulation, justifying the need for better understanding
of daily medical practices in terms of use of growth factors to
prevent chemotherapy (CT)-induced neutropenia.